Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

greekman---------thanks for that, I was certain that I'd read the cost was 50k and whilst I wouldn't believe anything emanating from the House of Commons, I bow to your superior knowledge of DEMG, apologies for misleading. I hold these, having paid slightly more than their current sp, so I want them to rise. Meanwhile I'll check my notes for the error.
2517

2517,

No problem. It took me ages to find anything relating to the CardioQ cost per unit.
Re your comment House of Commons, you are obviously doubting our respected members of parliament. I chose this report as obviously every word is true. Surely you don't mean to give the impression that they tell less than the truth. You will be saying next that you don't believe our most eminent leader, and his merry men. Don't forget that we are not like those corrupt countries we read about. We are a democracy. I fully trust the government with my pension, health, education and future. OK I have no choice, otherwise the whole pathetic lot would be out.
Sorry to go off thread. Had my ramble now, but it is a fact that we have a fantastic, no brainer piece of kit, that the powers that be are paid vast overrated salaries to deny it's use.
As to the unit cost, if anyone can confirm pricing I would appreciate it.
As 2517 states House of Commons reports do have a habit of getting facts and figures wrong.

That house of commons report you're referring to is a collection of written evidence submitted by anyone who wants to submit it. See it on http://www.parliament.uk/healthcom/ and look under "NHS Deficits" where they have a link to the report itself.

It looks like you're quoting Deltex's written evidence and Deltex are quoting Patricia Hewitt. If P.H. was referring directly to the CardioQ, that's good. I didn't know that.

On reading the article fully, it does look like P H was using Deltex as an example to many other innovative money saving ideas.
But as said, all they (the politicians) do is talk.

Very strange.
This share has slowly crept up today, on very little volume.
A total of 163,73 dealt today, all buys, sp up almost 9%. Why.

Nice rise for the day. 2p, 11.76% rise, on what for August and Deltex average volume, not bad at all.

And yet another fantastic result from a clinical trial.
What the h..l are the NHS waiting for. This must be one of the best no brainer products in the medical world.
Big problem for NHS management, 'We have a product that will pay for itself in less than 1 year, and after that save thousands of pounds per monitor.
Q. Do you want it?
A. We will have to think about it, after all there have only been about 50 plus such results. Give us a few more months (years) to think about it whilst we continue drawing our overrated salaries and we will let you know.

The USA in my opinion is the way forward at least for the near to medium term. It will be then that the NHS catches up as usual.
Deltex... Brilliant.
NHS... Pathetic

Yes greekman excellent results yet again, somebody in authority needs to kick a--- and make the Cardio-Q available in every hospital in Britain, let's face it , it's our money and wellbeing they are mucking around with.
2517

THE COUNT--->ALL

I've just caught up with all the posts on here made over the last month or so. The cost of a DEMG monitor is ABSOLUTELY NO WAY anything like 50,000. It is, as GREEKMAN has stated, circa 7,000. Such is the price elasticity within the NHS that they actually put up the cost by an extra 1,000 because the price has no really significant contribution to make in this particular decion making process...such is the farcical way the NHS is being run.

I think it is also clear, from the recent pre-close trading statement that monitor sales have not continued at the rate they started the year at. But from the existing installed base alone, there is still quite massive potential to increase probe sales as monitors are being so under utilised in the majority of cases. I have been told that even with no new monitor sales (and this was before the last set of results), that the company still expects to hit profitabilty shortly, just on probe growth alone for the existing base of machines. But of course, they will still sell monitors too and this should speed up the process. I am expecting quarterly profitability by Q4 of this year, or Q1 of next financial year at the latest.

I also made the following post over on the 'dark side' which might be useful to some.

Regards,

THE COUNT!



The Count - 1 Sep'06 - 13:19 - 1246 of 1248 edit

THE COUNT--->ALL

OK, here are the basics of the Charles Stanley Deltex comment. First of all, it comments on the actual trial itself. That is pretty much as per the RNS.

But it does confirm one other important thing. There were no actual recorded deaths...the trial was not designed for this anyway. The typical death rate in the NHS for this type of operation runs at 7%. The study covered 108 patients so it would have been within reasonable expectation to see even a single death, but the lack of deaths could still be a statisitical anomaly. CS consider this study along with an earlier study where there were no deaths and show that the odds of it not being statistically significant equate to 3,000 to 1.

CS therefore then advise that if you, or any member of your family are about to go in for major surgery, to make sure the hospital uses the CardioQ....or else!!!!!

So, after taking in the expected, yet still remarkable results of this independent study, in a hospital which was already a centre of excellence for this type of surgery, they conclude that the remarks by Mr Alan Horgan, the Consultant Colorectal Surgeon at the Freeman Hospital, were more than fully justified.

And once again, for the record, he said.....'These results are remarkable. Everyone involved in surgery and NHS management should read this study.'

They also re-iterate once again, that in the operating theatre where this trial was based, the Deltex CardioQ is the only monitoring system proven in clinical trials to deliver real benefit to patients.

The Freeman Hospital has historically had much better average results that the NHS in general. So this is not a hospital with a poor record moving towards the average, but a centre of excellence improving on an already better than average outcome.

I also want to add at this point, what I have said many times before, the operating theatre useage of this product has been pioneered by DEMG, and all studies to date on the use of oesophaegial doppler monitoring to optimally manage patient fluid levels in theatre have come from DEMG, and all this is in a market estimated to be 10 times the size of the intensive care market where there are several companies competing.

They then mention both LID and DEMG under the heading....'A substantial Valuation Anomaly'. They claim that theses are the two companies with effective minimally invasive systems. But DEMG's system is the only system that can be used in the op theatre as well as in intensive care (ICU). Within the UK, the most developed market, penetration is still only running at 2%. In the UK certainly, only a 'quite small' proportion of patients go through ICU and therefore (as I have argued time and time again on this thread), the potential market for DEMG is greater. It is not mentioned in the CS note, but I have been told this market is around 10 times the size of ICU. CS do maintain however, that LID's offering is attractive in ICU, especially for long stay patients.

They argue that there is a substantial valuation difference. In terms of volume sales, DEMG is the much larger of the two, despite similar revenue figures, and this is down to the fact that the LID cost is much larger. They then argue that DEMG should actually have a greater valuation whilst at the same time not claiming that LID is overvalued in any way. In other words, DEMG should be valued substantially higher, yet LID's valuation is currently about 50% higher than that of DEMG's....hence the 'anomaly'. I would argue that it is more a travesty than an anomaly but then again, I would, wouldn't I?

If we were valued at about the same price as LID, we should be on a price of 30p. They do qualify this by saying that they do not undertake full research on LID. They have tried to do so but despite their requests, they have never been invited to any analyst presentations given by LID.

[EDIT: I forgot to include the comment on coming newsflow. They mention that even though there is now evidence of increasing interest in the US, we should expect more in the short term from the European market. In September, there will be major conferences at which papers on the oesophaegeal doppler monitor will be presented including the Freeman study itself.]


CS do have a STRONG BUY rating on the stock as they believe when targetted volume management becomes a standard of care, the company will command a valuation multiples of where it is today.

I could have told them all that myself!!!!

What's more, the current large European trial will almost certainly establish a statistically significant effect on patient mortality and then, apart from financial reasons (and financing decisions made by comlete idiots) being the prime reasons for not financing the use of this technology, they will also faced with an ethical reason. All this combined with the already unarguable clinical evidence, should on balance, help to start tipping the balance further in our favour. I strongly believe it is all just a matter of time, and that is the reason I have taken such a large stake.

I just hope I live long enough to see it all happen. This is a bit of a joke between the chairman Nigel Keen and myself...but he is the older of the two of us so he'd better hurry up and deliver. :-)

Regards,

THE COUNT!

Hi The Count,

First of all nice to hear from you. Been a while.
What I think is required is a wake up call.
It needs a public outcry that in addition to the NHS not spending 1 pound to save 10, is that patients are spending longer in hospital than is necessary.
If I were a director of DELTEX I would be contacting every media outlet I could think of to spread the word on Deltex's must have product and the NHS (the governments ) inability to see the trees for the forest.
It has been suggested in 1 report (can't remember where and going on hols so no time to look) that potential patients ask if their proposed operation is being monitored re 'Fluid-balance by the CardioQ. If not they should ask why not.

So again no real change from last quarter, still no sales, same speculation and ever declining cash, another placing when?

http://www.timesonline.co.uk/newspaper/0,,175-2360082,00.html

Surgical breakthrough could save NHS up to 500m a year
By Nigel Hawkes, Health Editor
THE National Health Service could save at least 500 million a year by adopting techniques that could halve the recovery time of patients after surgery.

A new trial at the Freeman Hospital in Newcastle upon Tyne has shown that bowel surgery patients were ready to be discharged in just 7 days, rather than 14.



The surgeons told a conference in Lisbon yesterday that better preparation and education of patients, greater use of keyhole surgery and a technique for improving fluid balance and blood circulation during and after surgery could greatly reduce the recovery period.

The trial was the latest evidence of the effectiveness of CardioQ, a blood monitoring device developed by a British company, Deltex Medical.

If repeated across the country, the savings to the health service would exceed last years NHS deficit of 500 million. However, the device was used in fewer than 5 per cent of possible NHS procedures, reflecting the difficulty of getting new devices used by the service.

Alan Horgan, consultant colorectal surgeon at the Freeman Hospital and leader of the study, said: These results are remarkable. Everyone involved in surgery and NHS management should read this study.

Fluid-balance during and after surgery is incredibly important to patient wellbeing. Our surgical recovery programme means the Freeman Hospital is already a leader in recovery times, but the CardioQ has allowed us to get even better. We have proven that it is possible to save the NHS both time and money, while also enhancing patient care.

CardioQ works by monitoring how much blood the heart is pumping. Blood lost during operations is topped up by using a colloidal solution that mimics the behaviour of blood. Getting the volume exactly right is critical to ensuring that sufficient oxygen is delivered to the organs. Too little can lead to organ failure and even death. But too much can cause heart failure, so doctors have had to tread a fine line between the two.

CardioQ monitors blood volume using an ultrasound probe inserted down the throat. The probe measures blood flow by bouncing ultrasound waves off blood cells flowing through the aorta, the main blood vessel.

The trial covered 108 patients. Half were given fluid at the discretion of the anaesthetist, while the other half had their fluid levels monitored by CardioQ.

The national average recovery time for bowel surgery is 14 days, but at the Freeman, discharge took an average of only 7 days. The largest part of the improvement was the result of the recovery programme, which included the use of keyhole surgery.

But CardioQ also contributed another two days, and patients treated with it also had far fewer post-operative complications 2 per cent rather than 15 per cent. None needed an unplanned admission to the critical care unit, compared with 11 per cent of patients not treated using CardioQ.

Every day in a general or surgical ward costs 400 per patient. The CardioQ monitor costs 7,000 and the probes used in the trial 55 each, meaning that the monitor could pay for itself in days. It could be used for a range of operations, not just those on the bowel.

The National Institute for Health and Clinical Excellence described CardioQ as standard clinical practice. Yet such is the reluctance of the NHS to adopt new approaches that it is used in fewer than one in twenty operations in which it could provide benefits.

Ewan Phillips, managing director of Deltex Medical, said: Embracing this technology should be a no-brainer.

Just need to get the message through to the numpties holding the purse strings at the NHS.
2517

The above article (post 310) is very impressive when you see it in The Times. It's on page 4 in the main news section and takes up two thirds of a page. The headline is quite large. It's fantastic P.R.

We have said it many times, that the decision re purchase/use of the CardioQ is a no brainer.
The conference attended by 600 colorectal surgeons from the UK, Europe and the USA MUST finally allow those in authority in the UK (the NHS managers,sorry mis-managers) to see that they really have no alternative but to go for it.
I expect the institutions, such as First State has recently to increase their holdings and hopefully none holding institutions to start buying in.
As ever though nothing in this game is guaranteed.
So I won't hold by breath where this countries health institutions are concerned.
I have held the believe for many months now that Deltex's near to medium future is overseas.

Yet another cracking RNS.
Increased sales with new contracts must surely now be just round the corner.
I would think those linked to Deltex must feel like that wall they are continually banging their heads against is finally starting to crumble.
If ever patience is tried it is being involved in this share.
When will the powers that be wake up to this no brainer.
I would be amazed if we reach the end of 2006 without a significant rise in the sp.

The message is slowly being spread ever wider, and surely some of the surgeons at that conference will get the message home to the powers that be who 'manage' their hospitals and health care services, whether in the USA, Europe or NHS.
2517

Here we go back down again, infuriating.
2517

The results overall in my opinion look good, especially as they were the six months to end of June. Look what we have heard/read since.

From the results......
Turnover increased by over 20% in direct markets
25% increase in gross profit
1,241,000 in new equity raised after expenses (including 585,000
announced in this results statement)
It appears the increased six month loss due to the one offs has jittered the market.
My focus is definitely on the next six months. In my opinion end of 2006 start of 2007 will be very telling for Deltex.

The disposable probe that will make money for Deltex.. Just out the Interim Results for Deltex.. Take a look at the company website.. www.deltexmedical.com and probe the contents..

The probe is now being used in over 30 countries.. its the key to turnover and profits.. There are over 1,250 CardioQTM in use.. To back up the CardioQTM there are more than 90 clinical publication.. that have proven time and again its safe use, life saving and cost saving of the CardioQ.

Deltex product is getting stronger with each day that gos by.. Are you in on this one..?